Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Gross, M. E. [1 ]
Soscia, J. [1 ]
Sakowsky, S. [1 ]
Castellanos, O. [1 ]
Agus, D. B. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5154
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity
    Ross, R. W.
    Manola, J.
    Oh, W. K.
    Ryan, C.
    Kim, J.
    Rastarhuyeva, I.
    Yap, J. T.
    Van Den Abbeele, A. D.
    Kantoff, P. W.
    Taplin, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
    Nakabayashi, Mari
    Werner, Lilian
    Courtney, Kevin D.
    Buckle, Geoffrey
    Oh, William K.
    Bubley, Glen J.
    Hayes, Julia H.
    Weckstein, Douglas
    Elfiky, Aymen
    Sims, Danny M.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    [J]. BJU INTERNATIONAL, 2012, 110 (11) : 1729 - 1735
  • [3] Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC)
    Buckle, G. C.
    Werner, L.
    Oh, W. K.
    Bubley, G.
    Hayes, J. H.
    Weckstein, D.
    Elfiky, A.
    Sims, D. M.
    Kantoff, P.
    Taplin, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)
    Gross, Mitchell E.
    Dorff, Tanya B.
    Quinn, David I.
    Diaz, Patricia M.
    Castellanos, Olga O.
    Agus, David B.
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E11 - E21
  • [5] Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel
    Duran, Ignacio
    Montagut, Clara
    Calvo, Emiliano
    Galtes, Susana
    Navarrete, Alicia
    Rodriguez-Pascual, Jesus
    Hidalgo, Manuel
    Francisco Rodriguez-Moreno, Juan
    Cubillo, Antonio
    Garcia, Antonia
    Sanchez, Lorena
    Barbas, Coral
    Viqueira, Andrea
    Bellmunt, Joaquim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [6] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC).
    Gross, Mitchell E.
    Dorff, Tanya B.
    Quinn, David I.
    Massopust, Kristy
    Diaz, Patricia M.
    Castellanos, Olga O.
    Agus, David B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    [J]. UROLOGE, 2014, 53 (03): : 391 - 399
  • [9] Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Chi, K. N.
    Vaishampayan, U.
    Hotte, S.
    Vogelzang, N.
    Alumkal, J.
    Agrawal, M.
    Nydam, T. M.
    Fandi, A.
    Scher, H. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Gulley, James L.
    Arlen, Philip M.
    Woo, Sukyung
    Steinberg, Seth M.
    Wright, John J.
    Parnes, Howard L.
    Trepel, Jane B.
    Lee, Min-Jung
    Kim, Yeong Sang
    Sun, Haihao
    Madan, Ravi A.
    Latham, Lea
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2070 - 2076
12345